Cargando…
CD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction
Previous study from our lab has revealed a new role of CD47 in regulating adipose tissue function, energy homeostasis and the development of obesity and metabolic disease in CD47 deficient mice. In this study, the therapeutic potential of an antisense oligonucleotide (ASO) targeting to CD47 in obesi...
Autores principales: | Gwag, Taesik, Li, Dong, Ma, Eric, Guo, Zhenheng, Liang, Ying, Wang, Shuxia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935863/ https://www.ncbi.nlm.nih.gov/pubmed/36797364 http://dx.doi.org/10.1038/s41598-023-30006-2 |
Ejemplares similares
-
Thrombospondin1 antagonist peptide treatment attenuates obesity-associated chronic inflammation and metabolic disorders in a diet-induced obese mouse model
por: Zhou, Qi, et al.
Publicado: (2023) -
Antisense oligonucleotide‐mediated knockdown of Mpzl3 attenuates the negative metabolic effects of diet‐induced obesity in mice
por: Worley, Beth L., et al.
Publicado: (2021) -
Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019) -
Antisense oligonucleotide and thyroid hormone conjugates for obesity treatment
por: Cao, Yang, et al.
Publicado: (2017) -
Fetal antisense oligonucleotide therapy for congenital deafness and vestibular dysfunction
por: Wang, Lingyan, et al.
Publicado: (2020)